AI assistant
CVRx, Inc. — Director's Dealing 2024
Feb 2, 2024
33690_dirs_2024-02-02_c1eb7431-c474-4cf4-ba2c-01e268ea9f98.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: CVRx, Inc. (CVRX)
CIK: 0001235912
Period of Report: 2023-09-15
Reporting Person: Johnson & Johnson Innovation - JJDC, Inc. (N/A)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.237 | 2023-12-14 | Common Stock (237) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2024-11-18 | Common Stock (158) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2025-08-06 | Common Stock (189) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2025-08-06 | Common Stock (165) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2025-08-06 | Common Stock (118) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2025-08-06 | Common Stock (71) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2025-08-06 | Common Stock (23) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2025-11-09 | Common Stock (85) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2027-02-01 | Common Stock (758) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2027-02-01 | Common Stock (489) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2028-02-15 | Common Stock (758) | Direct | |
| Stock Option (Right to Buy) | $0.237 | 2028-02-15 | Common Stock (300) | Direct | |
| Stock Option (Right to Buy) | $1.186 | 2028-11-28 | Common Stock (758) | Direct | |
| Stock Option (Right to Buy) | $1.186 | 2028-11-28 | Common Stock (142) | Direct | |
| Stock Option (Right to Buy) | $3.955 | 2029-12-05 | Common Stock (758) | Direct | |
| Stock Option (Right to Buy) | $5.141 | 2031-01-04 | Common Stock (1264) | Direct |
Footnotes
F1: This Form 3 Amendment is being filed solely to report the Stock Options that were inadvertently omitted from the Form 3 filed by the Reporting Person on September 18, 2023. The beneficial ownership and pecuniary interest of Johnson & Johnson ("J&J") in the securities reported herein has not changed. On September 15, 2023, Johnson & Johnson Innovation - JJDC, Inc., a New Jersey corporation and wholly-owned subsidiary of J&J ("Old JJDC") completed an internal reorganization, whereby, through a series of transactions, Old JJDC merged with and into a newly-formed wholly-owned subsidiary of J&J organized under Delaware law,
F2: (Continued from footnote 1) ultimately resulting in all assets and securities owned by Old JJDC now being held by a Delaware corporation also named "Johnson & Johnson Innovation - JJDC, Inc." ("New JJDC"). By operation of law, the securities reported herein are now held directly by New JJDC. A separate Form 4 Amendment will be filed to disclose Old JJDC's disposition of the securities reported herein.
F3: Fully vested.
F4: Vests as to 1/48th of the shares each month commencing January 6, 2020.
F5: Vests as to 1/48th of the shares each month commencing January 11, 2021.